These studies generated immune risk scores by comparing Gal-9 level with immune cell TME infiltration, revealing Gal-9 as a biomarker of reoccurrence-free patient survival in SCLC and reduced survival in LCNEC. The gene discussed is LGALS9; the disease is small cell lung carcinoma.